Powder: -20°C for 3 years | In solvent: -80°C for 1 year
L-NMMA acetate (Tilarginine acetate) 是一氧化氮合酶抑制剂, 对其所有亚型均有抑制作用,包括 NOS1,NOS2和 NOS3。与 nNOS (大鼠), eNOS (人), 和 iNOS (小鼠)结合 的 Ki 值分别为0.18,0.4,6 µM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 298 | 现货 | ||
2 mg | ¥ 438 | 现货 | ||
5 mg | ¥ 739 | 现货 | ||
10 mg | ¥ 996 | 现货 | ||
25 mg | ¥ 1,890 | 现货 | ||
50 mg | ¥ 2,790 | 现货 | ||
100 mg | ¥ 3,970 | 现货 |
产品描述 | L-NMMA acetate (Tilarginine acetate) is an inhibitor of nitric oxide synthase of all NOS isoforms (i.e. NOS1, NOS2, and NOS3). The Ki values are 0.18, 0.4, and 6 µM for nNOS, eNOS, and iNOS, respectively. |
靶点活性 | nNOS:0.18 μM(Ki,rat), iNOS:6 μM(Ki,mouse), eNOS:0.4 μM(Ki,human) |
体外活性 | L-NMMA inhibits vasodilator responses to the endothelium-dependent vasodilator ACh but not to the endothelium-independent NP. L-NMMA does not affect isoprenaline-induced relaxation[2]. The inhibitory effect of L-NMMA is unchanged by previous incubation with D-arginine while it is prevented by L-arginine (L-Arg). L-NMMA, starting from 100 μM, produces a concentration-dependent inhibition of the evoked relaxations (2Hz); maximal inhibition at 1 mM averaged about 35%. The Superfusion of L-NMMA decreases arteriolar diameter and causes dose-dependent increases in arteriolar tone. The onset of action of L-NMMA is nearly immediate. NE induced dose-related vasoconstriction that is significantly potentiated by L-NMMA[3]. |
别名 | Tilarginine acetate, Methylarginine acetate |
分子量 | 248.28 |
分子式 | C9H20N4O4 |
CAS No. | 53308-83-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 50 mg/mL (201.39 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O | 1 mM | 4.0277 mL | 20.1386 mL | 40.2771 mL | 100.6928 mL |
5 mM | 0.8055 mL | 4.0277 mL | 8.0554 mL | 20.1386 mL | |
10 mM | 0.4028 mL | 2.0139 mL | 4.0277 mL | 10.0693 mL | |
20 mM | 0.2014 mL | 1.0069 mL | 2.0139 mL | 5.0346 mL | |
50 mM | 0.0806 mL | 0.4028 mL | 0.8055 mL | 2.0139 mL | |
100 mM | 0.0403 mL | 0.2014 mL | 0.4028 mL | 1.0069 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
L-NMMA acetate 53308-83-1 Immunology/Inflammation NOS Tilarginine Acetate Tilarginine acetate Tilarginine Methylarginine L-NMMA Methylarginine acetate Nitric oxide synthases L NMMA acetate inhibit LNMMA acetate L-NMMA Acetate NO Synthase Inhibitor Methylarginine Acetate inhibitor